Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06171607 · ClinicalTrials.gov registry record · Phase 1
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
A Phase 1 study of Breast Carcinoma, sponsored by University of Southern California.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT06171607 is a Phase 1 study of Breast Carcinoma that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 100 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06171607, a Phase 1 study of Breast Carcinoma, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial investigates the role of contrast enhanced ultrasound (CEUS) in identifying cystic breast masses as benign or malignant. Ultrasound is a diagnostic imaging test that uses sound waves to make pictures of the body without using radiation (x-rays). Ultrasounds are widely used to diagnose many diseases in the body. This trial may help researchers learn if using CEUS will help in determining whether or not an ultrasound guided biopsy is necessary.
Conditions Studied
Interventions
- DRUG Perflutren Lipid Microspheres
- PROCEDURE Contrast-Enhanced Ultrasound
- DRUG Sulfur Hexafluoride Lipid Microspheres
Study Locations (2)
California
- Los Angeles County-USC Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2027-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06171607
The ClinicalTrials.gov registry entry for NCT06171607 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (87% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Perflutren Lipid Microspheres is the first listed.
NCT06171607 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06171607 about?
NCT06171607 is a clinical study titled "Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses". This clinical trial investigates the role of contrast enhanced ultrasound (CEUS) in identifying cystic breast masses as benign or malignant. Ultrasound is a diagnostic imaging test that uses sound waves to make pictures of the body without using radiation (x-rays). Ultrasounds are widely used to dia...
What is the current status of trial NCT06171607?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2020-11-05. Estimated completion is 2027-11-05.
What conditions does trial NCT06171607 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT06171607?
The interventions under investigation include: Perflutren Lipid Microspheres (DRUG), Contrast-Enhanced Ultrasound (PROCEDURE), Sulfur Hexafluoride Lipid Microspheres (DRUG).
Who is sponsoring clinical trial NCT06171607?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06171607 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
RECRUITING · Phase 1
-
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
ACTIVE NOT RECRUITING · Phase 1
-
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.